Clinical Trials Directory

Trials / Terminated

TerminatedNCT00387426

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
14 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial is studying how well sunitinib works in treating patients with idiopathic myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells.

Detailed description

PRIMARY OBJECTIVE: I. Assess the response rate and the duration of response in patients with idiopathic myelofibrosis treated with sunitinib malate. SECONDARY OBJECTIVE: I. Assess the safety of sunitinib malate in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral sunitinib malate once daily for 6 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 4 weeks.

Conditions

Interventions

TypeNameDescription
DRUGsunitinib malateGiven PO

Timeline

Start date
2006-09-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2006-10-13
Last updated
2014-05-28
Results posted
2012-08-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00387426. Inclusion in this directory is not an endorsement.

Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) · Clinical Trials Directory